Pancreatitis News and Research RSS Feed - Pancreatitis News and Research

Pancreatitis is inflammation of the pancreas. The pancreas is a large gland behind the stomach and close to the duodenum—the first part of the small intestine. The pancreas secretes digestive juices, or enzymes, into the duodenum through a tube called the pancreatic duct. Pancreatic enzymes join with bile—a liquid produced in the liver and stored in the gallbladder—to digest food. The pancreas also releases the hormones insulin and glucagon into the bloodstream. These hormones help the body regulate the glucose it takes from food for energy.

Normally, digestive enzymes secreted by the pancreas do not become active until they reach the small intestine. But when the pancreas is inflamed, the enzymes inside it attack and damage the tissues that produce them.

Pancreatitis can be acute or chronic. Either form is serious and can lead to complications. In severe cases, bleeding, infection, and permanent tissue damage may occur.
CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

Cellular and Molecular Gastroenterology and Hepatology is committed to publishing impactful digestive biology research covering a broad spectrum of themes in GI, hepatology and pancreatology. We wanted to share two new CMGH articles, which both offer important insight into future interventions for chronic conditions. [More]
Study identifies risk factors for asparaginase-induced pancreatitis in ALL patients

Study identifies risk factors for asparaginase-induced pancreatitis in ALL patients

Researchers have identified a rare genetic variation associated with a dramatically increased risk of severe acute pancreatitis in acute lymphoblastic leukemia (ALL) patients treated with the chemotherapy agent asparaginase. St. Jude Children's Research Hospital led the study, which appears today in the Journal of Clinical Oncology. [More]
Newly identified molecular pathway could lead to new treatments for reflux, incontinence disorders

Newly identified molecular pathway could lead to new treatments for reflux, incontinence disorders

Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system. [More]
BIDMC investigators identify precise 5-gene classifier for discriminating early pancreatic cancer

BIDMC investigators identify precise 5-gene classifier for discriminating early pancreatic cancer

Pancreatic cancer, the fourth leading cause of cancer death in the United States, is often diagnosed at a late stage, when curative treatment is no longer possible. A team led by investigators at Beth Israel Deaconess Medical Center has now identified and validated an accurate 5-gene classifier for discriminating early pancreatic cancer from non-malignant tissue. [More]
SLU researchers discover compound that disrupts fibrotic process

SLU researchers discover compound that disrupts fibrotic process

Saint Louis University researchers have found that a type of compound that disrupts the process that causes fibrosis (scarring) in the lungs and liver also shows promise in preventing and treating fibrosis in yet another organ, the pancreas. The research was conducted in an animal model. [More]
Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME). [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Disease burden, health care costs higher in children with recurrent acute and chronic pancreatitis

Disease burden, health care costs higher in children with recurrent acute and chronic pancreatitis

The burden of recurrent acute and chronic pancreatitis in children may be higher than previously thought, with high costs related to repeated hospitalizations, report a pair of studies in the Journal of Pediatric Gastroenterology and Nutrition. [More]
MUSC researchers receive $1.68 million NIH grant to study better treatment for chronic pancreatitis, diabetes

MUSC researchers receive $1.68 million NIH grant to study better treatment for chronic pancreatitis, diabetes

MUSC researchers received a $1.68 million National Institutes of Health grant to explore a better treatment for chronic pancreatitis, with the hopes that it also may shed light on a future cure for patients with type 1 diabetes. [More]
CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

CytoSorbents partners with Hoang Long Pharma to bring CytoSorb to Vietnam

CytoSorbents Corporation, a leader in critical care immunotherapy commercializing its CytoSorb extracorporeal cytokine adsorber to control deadly inflammation using blood purification, today announced an exclusive multi-year distribution agreement with Hoang Long Pharma, a medical distributor in Vietnam specializing in the distribution of innovative pharmaceuticals, biologics, and devices to treat patients suffering from critical illnesses, immunologic disorders and deficiencies, and infections. [More]
Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. [More]
Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Pediatric chemotherapy regimen improves outcomes in young adults with ALL

Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult' treatment protocols, report Dana-Farber Cancer Institute scientists. [More]
Gallstones, statins increase risk of acute pancreatitis, shows study

Gallstones, statins increase risk of acute pancreatitis, shows study

Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three idiopathic pancreatitis patients. [More]
Comorbidities relevant to CML TKI choice common

Comorbidities relevant to CML TKI choice common

Comorbid conditions that could affect the choice of tyrosine kinase inhibitor are common in patients with chronic myeloid leukaemia, finds an analysis of a US claims database. [More]
Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's ALIMTA (pemetrexed for injection) and Merck's KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). [More]
Intravenous PEG-asparaginase use recommended in paediatric ALL

Intravenous PEG-asparaginase use recommended in paediatric ALL

Phase III trial results support the use of intravenously administered PEGylated Escherichia coli asparaginase as the preparation of choice in children and adolescents with acute lymphoblastic leukaemia. [More]
Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types. [More]
Lund University researchers reveal how the body develops acute pancreatitis

Lund University researchers reveal how the body develops acute pancreatitis

Researchers at Lund University in Sweden may have discovered one of the keys to understanding how the body develops acute pancreatitis. The results offer hope for the development of drugs that specifically target the disease. [More]
Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Liraglutide drug combined with diet and exercise promotes weight loss in diabetic patients

Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks compared with placebo, according to a study in the August 18 issue of JAMA. [More]
‘Medical foods’ for patients with rare IEMs may cause harm when not carefully managed

‘Medical foods’ for patients with rare IEMs may cause harm when not carefully managed

Many "medical foods" are designed to help manage patients with rare inborn errors of metabolism (IEMs), and can help prevent serious and life-threatening complications. However, such special foods may cause harm in some patients when their use is not carefully monitored and managed, according to a research team led by scientists at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health. [More]
Advertisement
Advertisement